Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
John W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan
Abstract
Practical considerations, potential barriers, and research gaps relating to sodium-glucose co-transporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in individuals with heart failure with preserved ejection fraction and obesity. HF, heart failure; SGLT2i, sodium-glucose co-transporter 2 inhibitor
Topics & Concepts
MedicineHeart failureEjection fractionGlucagon-like peptide-1Internal medicineTransporterSodiumGlucagon-like peptide 1 receptorEndocrinologyReceptorPharmacologyCardiologyDiabetes mellitusAgonistBiochemistryType 2 diabetesChemistryGeneOrganic chemistryDiabetes Treatment and ManagementHeart Failure Treatment and ManagementElectrolyte and hormonal disorders